Uptake of isoleucine, leucine, and valine in Escherichia coli K-12 is due to several transport processes for which kinetic evidence has been reported elsewhere. A very-high-affinity transport process, a high-affinity transport process, and three different low-affinity transport processes were described. In this paper the existence of these transport processes is confirmed by the isolation and preliminary characterization of mutants altered in one or more of them. The very-high-affinity transport process is missing either in strains carrying the bmR6am mutation or in strains carrying the brn-8 mutation. This appears to be a pleiotropic effect since other transport systems are also missing. Mutant analysis shows that more than one transport system with high affinity is present. One of them, high-affinity 1, which needs the activity of a protein produced by the brnQ gene, transports isoleucine, leucine, and valine and is unaffected by threonine. The other, high-affinity 2, which needs the activity of a protein produced by the bmnS gene, transports isoleucine, leucine, and valine; this uptake is inhibited by threonine which probably is a substrate. Another protein, produced by the bmR gene, is required for uptake through both high-affinity 1 and high-affinity 2 transport systems. The two systems therefore appear to work in parallel, brnR being a branching point. The brnQ gene is located close tophoA at 9.5 min on the chromosome of E. coli, the brnR gene is located close to lac at 9.0 min, and the bmnS gene is close to pdxA at 1 min. A mutant lacking the low-affinity transport system for isoleucine was isolated from a strain in which the high-affinity system was missing because of a brnR mutation. This strain also required isoleucine for growth because of an ilvA mutation. The mutant lacking the low-affinity transport system was unable to grow on isoleucine but could grow on glycylisoleucine. This mutant had lost the low-affinity transport for isoleucine, whereas those for leucine and valine were unaffected. A pleiotropic consequence of this mutation (brn-8) was a complete absence of the very-high-affinity transport system due either to the alteration of a common gene product or to any kind of secondary interference which inhibits it. Mutants altered in isoleucine-leucinevaline transport were isolated by taking advantage of the inhibition that valine exerts on the K-12 strain of E. coli. Mutants resistant both to valine inhibition (Valr) and to glycylvaline inhibition are regulatory mutants. Valr mutants that are sensitive to glycylvaline inhibition are transport mutants. When the very-high-affinity transport process is repressed (for example by methionine) the frequency of transport mutants among Valr mutants is higher, and it is even higher if the high-affinity transport process is partially inhibited by leucine.
valine action, or are transport mutants which cannot concentrate external valine because of a transport defect. Since E. coli K-12 has a transport system for dipeptides (3), which are concentrated and then cleaved inside the cell into the constituent amino acids (13) , a mutant altered in valine transport should be resistant to valine but sensitive to valine-containing dipeptides. We have already used (3, 8) this criterion to define a transport mutant.
In this paper we describe the isolation and preliminary characterization of mutants that are altered either in the very-high-affinity transport system for isoleucine, leucine, and valine (7) , in the high-affinity transport system for isoleucine, leucine, and valine, or in the low-affinity transport system for isoleucine. We did not try to isolate mutants in which the other two low-affinity transport systems (for leucine and valine, respectively) was altered, but a possible selection procedure is indicated. The results obtained make this system an attractive one for a study on structure and function of specific membrane proteins.
A preliminary account of this work has been published (8) and reported (J. Guardiola, M. De Felice, and M. laccarino, Lunteren Lectures on Molecular Genetics, Lunteren, The Netherlands, 1971).
MATERIALS AND METHODS Bacterial strains. Table 1 lists the strains used, and Fig. 1 indicates the map order of the relevant markers according to Taylor and Trotter (18) .
Reagents. Reagents whose source is not mentioned here were of the highest purity commercially available. Amino acids used were all L-form, unless otherwise mentioned. Glycylvaline was obtained from Sigma Chemical Co., St. Louis, Mo. Uniformly "4C-labeled L-amino acids were obtained from New England Nuclear Corp., Boston, Mass. N-methyl-Nnitro-N-nitrosoguanidine (nitrosoguanidine) was purchased from K and K Laboratories, Inc., Plainview, N.Y.
Media. The minimal medium used was minimal citrate (20) . Usual supplements, when required, were 0.4% glucose, 25 gg of tryptophan per ml, 100 /g of arginine per ml, 50 ,ug of other amino acids per ml, 50 gg of nucleosides per ml, and 10 ug thiamine per ml.
Rich media were L-broth (12) derivative carrying a temperature-sensitive immunity and the genes for resistance to chloramphenicol (15) . With this phage, chloramphenicol-resistant, temperature-sensitive lysogens were isolated; clones were grown in rich liquid medium and then induced for 10 min at 42 C, to produce high titers of P1. Transductions were performed on minimal citrate plates as described by Hill et al. (9) . Mutagenesis. For nitrosoguanidine mutagenesis, a culture was grown overnight in minimal medium, centrifuged, washed in unsupplemented minimal medium, resuspended in the same medium at the original concentration, and shaken for 30 min at 37 C in the presence of 30 ug of the mutagen per ml. A 10-fold dilution of this suspension was grown overnight in appropriately supplemented medium.
Ultraviolet mutagenesis was performed by irradiating a bacterial suspension at a dose that kills about 95% of the bacteria.
Isolation of independent Valr mutants. A suspension of bacteria was diluted to a concentration of about 100 cells per ml in a minimal medium containing. all the supplements needed by that strain for growth. The suspension was divided into 1-ml portions which were grown overnight. From each tube, 0.1 ml was spread on plates supplemented with valine and other supplements, as described in the text. From each plate only one colony was purified and retained for further characterization. Isolation procedures different from this one are detailed in the text.
Test for amber mutations. To check whether the phenotype of a mutant was due to an amber mutation, a given strain was lysogenized either with 80psu3 (prepared from strain 594) or with 080, as a control. The lysogens were immune to both 080s but sensitive to 480vir; the 4t80 lysogens supported the growth of phage T4 but not of phage T4 containing the mutation amB17 in gene 23 (obtained from A. Coppo and J. F. Pulitzer). The i80psu3 lysogens supported the growth of both phages. The relevant phenotype was checked on the strain to be tested and the corresponding 080psu3 lysogen.
Transport assays. Transport was measured as described previously (7) .
RESULTS
Selection of mutants. In the preceding paper (7), we showed that multiple transport processes for branched-chain amino acids are present in E. coli K-12, and therefore it should be difficult to isolate transport mutants. On the other hand, mutants which appear to have an altered uptake of the branched-chain amimo acids have been described (8) . Therefore, we have tried to rationalize the selection of mutants on the basis of the kinetic characterization of the different transport processes for branched-chain amino acids (7) and of the characteristics of the mutants isolated previously (8) .
As shown previously (7), a very-high-affinity transport process with a Km value in the 10-' M range exists in E. coli K-12; this transport process takes up isoleucine, leucine, and valine cThese mutants were isolated from strain Ca85, and the plates contained the other supplements required by this strain for growth. They were, therefore, all Valr even in the absence of leucine.
d All of these mutants were also resistant to valine if leucine was substituted with threonine.
eForty-six of these forty-eight mutants were also resistant to valine if leucine was present.
easily found if the very-high-affinity transport process is repressed by methionine, and this fact confirms the physiological role of this transport process. Their frequency is even higher if the high-affinity transport process is partially inhibited by either leucine or threonine. The presence of the low-affinity transport processes does not appear to prevent the finding of transport mutants. We believe that this is due either to the low-affinity of the substrates for these transport processes or to their poor contribution to the pool size.
Mutations pleiotropically affecting the very-high-affinity transport process. Two different mutants, whose isolation is described below, show decreased uptake through the veryhigh-affinity transport process as a consequence of specific mutations. The phenotype, however, is pleiotropic because other transport systems are also affected. One of these mutants, MI250 (bmQ2, bmR3, brn-8), shows essentially no uptake through the very-high-affinity transport process for isoleucine, leucine, or valine (see Table 3 ); the mutation causing this effect was called bm-8 and affects the low-affinity transport process for isoleucine (see below). The other strain, MI247brnR6am (data not reported), shows less than 10% of the uptake through the very-high-affinity transport for branched-chain amino acids shown by an isogenic brnR+ strain. The mutation causing this effect, brnR6, is an amber mutation and is 93% co-transducible with lac.
For both mutants, two alternative explanations are possible: (i) either a gene product common to two different transport systems is nonfunctional or lacking as a consequence of a single mutation; or (ii) because of the mutation, there is a secondary alteration of uptake (dup, for example, to altered pool size or amino acid excretion).
Multiplicity of the high-affinity transport systems. The brnQ2 mutant described previously (8) is resistant to valine inhibition only'if leucine is also present in the growth medium, and the action of leucine is most probably related to the inhibition of valine uptake"which leucine exerts either on the wild-type strain or the brnQ2 mutant (see Table 4 ). In fact, leucylhistidine, which presumably does not inhibit valine uptake, cannot substitute for leucine in the expression of valine resistance. We therefore concluded (8) that the observed leakiness of the phenotype was caused either by a partial alteration of the transport system for branched-chain amino acids or by a more or less complete alteration of one of several transport systems for these amino acids. The finding of several transport processes for branched-chain amino acids (7) makes the second hypothesis more likely and permits one to define conditions in which at least 90% of the rate of amino acid uptake is due to one specific transport process. As a consequence, each transport process can be analyzed separately to check which one is altered. Measurement of the high-affinity transport process in strain MI174b (brnQ2) confirmed that the alteration described previously (8) was in the apparent Vmax value and not in the Km value; moreover, difficulties in reproducibility led to the finding that the high-affinity transport process is unstable. This instability is greater in strain MI174b than in strain MI148a (brn+) (data not reported). Instability takes place under conditions of amino acid starvation even before this affects the growth rate; since the uptake rate is unstable also in chloramphenicoltreated cells, instability is probably due to protein turnover. Reproducible values could be obtained if bacteria were collected in midlogarithmic phase in which at least 50% of the added amino acids were still present and if uptake was measured exactly 10 min after chloramphenicol addition. Under these conditions only a small alteration in isoleucine, leucine, and valine uptake was found in strain MI174b as compared to the isogenic brn+ strain (see Tables 5 and 11 ). Because of this result, we made two alternative hypotheses: (i) there are two different high-affinity transport systems for branched-chain amino acids with very similar apparent Km and Vmax, and only one of them is missing in strain MI174b as a result of the brnQ2 mutation; (ii) the brnQ gene product is still partially active in strain MI174b. The experiments described hereafter demonstrate that the first hypothesis is correct.
If two different high-affinity transport systems do exist, it is likely that, although one of them transports only isoleucine, leucine, and valine, the other might transport some other amino acid(s). Therefore, we examined inhibition by different amino acids also in strain MI174b, and in this way we found that threonine totally inhibits valine uptake in this strain (Table 4 ). This observation suggests that threonine exerts its action on the fraction of uptake through the high-affinity transport that is left unaffected by the brnQ2 mutation. The action of threonine is shown in more detail in Table  5 -threonine also inhibits isoleucine and leucine uptake, and again the observed inhibition is much stronger in strain MI174b than in strain MI148a (brn+). The apparent inhibition constants of threonine inhibition of valine uptake in strains MI148a and MI174b are 9 x 10-4 and 6 x 10-6 M, respectively (Fig. 2) . We believe that threonine inhibition of valine uptake in strain MI148a takes place not only with low affinity (K 9 x 10-4 M) but also with highaffinity (K1 6 x 10-6 M), but this is difficult to prove because the high-affinity inhibition affects only a fraction of valine uptake.
The striking inhibition of valine uptake by Arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, histidine, lysine, phenylalanine, proline, serine, tyrosine, and tryptophan have no effect on the valine uptake either in MI148a or MI174b.
c Micromoles per 0.5 min per g of cells. Table 1 found to require the presence of threonine or leucine to express the resistance to valine. All five mutants appeared to be altered in the brnQ locus on the basis of co-transduction frequency of the Valr phenotype with lac. In fact, when these five mutants were treated with P1 phage grown on a brnQ+, lac+ strain and Lac+ transductants were selected, about 12% co-transduction frequency of the Valr phenotype was observed. These mutants were lysogenized with 080psu3; Lac+ colonies were purified and their resistance to valine was checked; four of these five mutants had become sensitive to valine. Two of these four Val8 mutants were cured of 080psu3, and both were found to have become again Lac-and Valr.
It has been reported (16) that amber mutations are sometimes leaky and that their leakiness decreases when a strA mutation is introduced into the strain. We further examined one of the amber Valr mutants by introducing the strA120 mutation of strain AT2365 (by P1 transduction) into it. The Valr phenotype did not change. Thus, it was probably due to the absence of the gene product and not to a low concentration of a normal, or missense, gene product obtained by misreading of the amber triplet. In conclusion, four independently isolated amber mutations in the brnQ locus make strain Ca85 resistant to valine (if threonine is also present). In one of these mutants, called MI238, the high-affinity transport process was analyzed and compared to that of its isogenic brn+ strain Ca85. As shown in Table 10 , uptake of isoleucine, leucine, and valine is slightly altered as in strain MI174b (Table 5) . Threonine abolishes almost completely this uptake (data not reported). Therefore, the phenotype of the strains carrying an amber mutation at the brnQ locus and of strain MI174b is not due to a partially active brnQ gene product, but to the absence of the activity of the brnQ gene product.
We will call hereafter the two high-affinity transport systems high-affinity 1 (the one that requires the brnQ gene product) and high-affinity 2 (the one that is inhibited by threonine). Mutants with defects in the latter system were isolated in the following way. The high-affinity transport of one of the branched-chain amino acids is inhibited completely by the other two. Therefore both the high-affinity 1 and the high-affinity 2 systems transport at least isoleucine, leucine, and valine. Moreover, the highaffinity 2 system should transport also threonine (Table 5) . Therefore a strain missing the high-affinity 2 system should be Valr and the resistance should not be helped by threonine. On the other hand, when the high-affinity 2 system is missing, the high-affinity 1 system is still active and, therefore, leucine should be required to inhibit the residual valine uptake. Finally, the resistance to valine should be expressed only if the very high-affinity transport system is nonfunctional, for example because of addition of methionine. Mutants altered in the high-affinity 2 transport system were isolated by selecting spontaneous Valr mutants from strain Ca85 (brn+). A flask containing 250 ml of minimal citrate supplemented with thiamine, histidine, 50 ,ug of methionine per ml, 20 ,g of valine per ml, and 50 ,ug of leucine per ml was inoculated with 2 x 109 bacteria. When full growth occurred (36 h at 37 C with aeration), a penicillin counterselection (6) Tables 6, 7 and 8 show that the bmnS locus is located between pyrA and ara (see Fig.  1 ), very close to pdxA (95% co-transduction: 46/48).
The initial rate of valine uptake in strain MI248 was assayed under conditions in which mainly high-affinity transport process is measured (same as those of Table 4 ). Under these conditions (Table 9) , the parental strain, Ca85, gave a value of 0.94 ,umol per 0.5 min per g of cells, whereas strain MI248 gave a value of 0.51 ,gmol per 0.5 min per g of cells. Also, isoleucine and leucine uptake are only slightly reduced, as it should be if, in strain MI248, high-affinity 2 is missing and high-affinity 1 is still functional. As expected (since the resistance to valine is not helped by threonine), threonine gave only very little inhibition. Strains carrying brnQ mutations show only partial uptake alterations (see, for example, Table 11 ); strains carrying bmnS mutations show also only partial uptake alterations (Table 9) ; however, when a strain is constructed which carries mutations at both genes brnQ and bmnS the high-affinity transport process is abolished. Such a strain was constructed by treating strain MI248 (bmS7, brnQ+, lac) with P1 grown on strain MI174b (brnQ2, lac+). Selection was made for Lac+ transductants, and among these about 15 to 20% were found to be Valr even in the absence of leucine. One of these Valr transductants was purified twice by single-colony isolation and named strain MI249 (brnS7, brnQ2; lac+). The brnQ2 mutation was demonstrated to be present in this strain by rescue with a proper P1 transduction. Uptake of valine in strain MI249 can still be measured if higher substrate concentrations are used. This uptake was shown to be done through the low-affinity transport since it had a Km value of 0.5-10-4 M (Fig. 4 ). An experiment similar to that of Fig. 4 (not reported) gave an analogous result for leucine. In Table 10 , measurements of the high-affinity transport process of isoleucine, leucine, and valine in the wild-type strain, in a strain missing high-affinity 1 system (MI238), in a strain missing high-affinity 2 system (MI248), and in a strain missing both the high-affinity 1 (17) . In the more recent edition of the linkage map of E. coli K-12 (18), the order proB, lac, phoA, and proC is reported. We use the previous order since it is supported by these results. The bmR and brnQ markers are arbitrarily drawn on the right side of lac and phoA, respectively. A three-point test experiment (8) locates brnQ on the right side of proC. The co-transduction frequencies of phoA with brnQ and lac have also been reported (8) . Other data are taken from this paper.
Lac+ transductants are Valr in the absence of leucine or threonine, and these co-transduction frequencies are different from those reported (8) for brnQ with these markers. Moreover, when strain AT2477 (proB28, brnR+) is treated with P1 grown on MI237 (proB+, brnR3), 91% (86/95) of the selected Pro+ transductants are Valr. Since the co-transduction frequency of the brnQ2 mutation is 12.5% with lac (8), the brnR3 mutation (which shows 94% co-transduction with lac) is separated from bmQ but co-transducible with it. Moreover, since in the above transduction 94% of the selected Lac+ transductants were Valr even in the absence of leucine and since only 12 .5% of these transductants should contain both brnR3 and brnQ2 (see Fig.  6 ), the phenotype of most of these transductants is due to the brnR3 mutation alone. Therefore the phenotype of a strain carrying the brnR3 mutation alone displays a level of resistance to valine equal to that of strain MI237 (brnQ2, brnR3).
Mutations in the bmR gene were also isolated in a single step. Spontaneous, independent mutants resistant to valine in the absence of leucine or threonine were isolated from strain Ca85 pregrown in the presence of methionine (methionine was also present during isolation; Kmi, micromolar; Vmax, micromoles of amino acid per 0.5 min per g of cells.
Concentration of inhibitors was 2 x 10-4 M. Methionine (50 jsg/ml) was present in the assay medium. For details see Materials and Methods.
see Table 2 ). Twenty-one Valr, but glycylvalinesensitive, mutants were purified and lysogenized with 480psu3; 8 of 21 became Vale and, therefore, were amber Valr mutants. One of the amber Valr mutants (MI247 [brnR6am 1) was treated with P1 grown on strain AT739 (lac+, brnR+), and Lac+ transductants were isolated; 93% (150/160) of these became Val", indicating that strain MI247 is altered at the bmR locus and that this locus is very close to lac. None of these Vals transductants was resistant to valine in the presence of threonine, and this shows that strain MI247 is brnQ+ (in fact, brnQ shows 12.5% co-transduction frequency with lac, see Fig. 6 ).
Transport assays were performed to confirm that the brnR mutation alone is able to abolish both high-affinity transport systems. Data of Table 10 show that strain MI247 (brnR6) has almost no uptake through the high-affinity transport process of either isoleucine or leucine or valine.
Mutant altered in the low-affinity transport system for isoleucine. It has been shown (7 and Table 11 ) that three different transport processes specific for either isoleucine or leucine or valine are present in E. coli. A mutant in the low-affinity transport system for isoleucine was isolated on the assumption that no other transport systems for isoleucine besides those described in this paper are present. Therefore, an isoleucine auxotroph missing all these transport systems should not be able to utilize isoleucine for growth, but should be able to utilize the isoleucine produced inside the cell from cleavage of a dipeptide containing isoleucine. Strain MI237b (ilvA, bmQ2, brnR3) was mutagenized with nitrosoguanidine, and a penicillin counter selection (6) Figure 7 shows the growth yield of strain M1250 grown on increasing concentrations of either isoleucine or glycylisoleucine, in the presence of methionine; no growth can be obtained on isoleucine, whereas a normal growth yield was obtained on glycylisoleucine, which satisfied our general criterion for identifying a transport mutant (3, 8) . The rates of uptake through the low-affinity transport of isoleucine, leucine, and valine were measured in strain M1250 and its bm-8+ parent MI237b (brnQ2, brnR3) (Table 12 ). In this experiment, the uptake through the very-high-affinity transport process is not measured in strain MI250 because a pleiotropic effect of the bm-8 mutation (Table 3) is an alteration of this transport system. Since the two strains were pregrown and then assayed in the presence of methionine, the very-high-affinity transport process, or at least most of it (7) is absent in the bm-8+ strain MI237b also. Furthermore, most of the uptake through the high-affinity transport is not present because of the brnQ2 and bmR3 mutations present in these two strains. The rate of isoleucine uptake via the low-affinity transport process was reduced in the mutant to 14% of the value in the parental (brn-8+) strain (Table 12) . Although to a lesser extent, leucine and valine uptake is also altered. This alteration is probably due to the observed pleiotropic effect of the brn-8 mutation. In fact, the fraction of the uptake through the very-high-affinity transport remaining in strain MI237b after repression might be higher than the fraction remaining in strain M1250. We cannot exclude, however, that the brn-8 mutation causes an effect at the level of the remaining transport processes or that it causes a secondary uptake alteration due, for example, to excretion of branched chain amino acids. Strain M1250, in fact, grows slowly on glycylisoleucine as compared to strain MI237b, perhaps because the isoleucine produced inside the cell is excreted. If true, this strain might also excrete leucine and valine.
DISCUSSION
The data reported in this paper confirm the necessity of mutant isolation to define a transport system. In fact, what appears from kinetic experiments to be only one transport system, namely the high-affinity one, is resolved into two different ones by mutant isolation. Moreover, the poor affinity and extreme specificity of the low-affinity transport processes made uncertain their existence until we found a mutant in which the isoleucine transport system was altered. However, when a transport mutant is defined, it is important to keep in mind that the transport assay is uptake of radioactive substrate and, therefore, the observed uptake alterations might be due to secondary effects of a mutation which causes an alteration at another level (e.g., regulation of pool size or excretion of amino acids). This is likely to be the case, as we had already suggested (8) , of a mutation in another gene, brnP (M. De Felice, J. Guardiola, T. Klopotowski and M. Iaccarino, manuscript in preparation). Therefore, we cannot exclude that the same is true for the mutants described in this paper. In particular, we cannot exclude that the pleiotropism shown by the strains bearing the brnR6am and the brn-8 mutations might be due to such a kind of secondary effects, which could have mimicked a genetic alteration of the very-high-affinity transport process.
The brnQ, brnR, and brnS genes described in this paper are different because of their chromosomal locations, and the brn-8 mutation is probably in a gene different from the other three, because the low-affinity transport process for isoleucine is still present in strains bearing amber mutations in the brnQ, brnR and bmnS genes. On the other hand, the different phenotype of two brnR mutations suggests the presence of another gene. In fact, in strain MI237b (brnR3) the very-high-affinity transport system and the low-affinity transport system for isoleucine are present, whereas in strain M1247 (brnR6am) the very-high-affinity transport system is missing, but the low-affinity transport system for isoleucine is present (data not shown). Although other interpretations are possible, a polar effect of the amber mutation brnR6 on an adjacent gene might be responsible for the phenotype. The location of the brnS gene is very similar to the location given by Glover (5) to the Valr-D locus, but it is different from the location of the ileS gene (10 The protein produced from the brnR gene appears to be analogous to the hisP protein described by Ames and Lever (1) . As in that case, our data can be interpreted with the brnQ and bmnS gene products working in parallel and both requiring the brnR gene product to permit transport through the membrane. It is not possible to decide whether the brnR gene product is more external or more internal as compared to the other two. A schematic representation of the situation is reported in Fig. -8 . Another possibility is that the brnR gene product is required for expression of the bmnS and brnQ genes.
In Table 13 a summary is reported of the different transport systems for branched-chain amino acids present in E. coli K-12. We have suggested in this table the presence of a leucinespecific transport system for which evidence has been reported by Furlong and Weiner (4). They report the isolation and purification of a leucine-specific binding protein from strain K-10 which is a derivative of the HfrC strain of K-12. This protein, used for experiments not reported in this paper, was isolated and purified from the osmotic shock fluid prepared from strain MI148a. The existence of a leucine-specific transport system with high affinity is also suggested by evidence reported previously (7 "The leucine-isoleucine-valine (LIV)-binding protein described by Penrose et al. (14) .
brnQ, brnR, and bmnS genes because the phenotype of an altered membrane gene product is likely to be complex, whereas the phenotype caused by an amber mutation is usually due to the absence of the gene product. Moreover, with these mutations the gene product can be identified as a protein. It is clear, however, that now it is possible to isolate mutations of different type (e.g., temperature sensitive or deletions) at the same loci. Column five in Table 13 is helpful for characterization of the different transport systems. These compounds inhibit the uptake of a radioactive substrate and might also be substrates of the specific transport system that they inhibit.
We examined the uptake of [4C ]threonine (experiment not reported) in strains MI148a (bm+) and MI174b (bmQ2). Isoleucine, leucine and valine gave no inhibition of the uptake, and this shows that either threonine is only an inhibitor and not a substrate of the high-affinity 2 transport system or that there is a multiplicity of transport systems also for threonine.
A column for gene products has been added in Table 13 only to point out that some gene products are proteins and that genes have yet to be found for the leucine-isoleucine-valine-binding protein (14) and for the leucine-binding protein (4) .
The differential sensitivity to valine and glycylvaline has proved very useful for isolation of the transport mutants described in this paper. Valine acts through the inhibition of isoleucine biosynthesis, and Valr mutants are of two types-either regulatory or transport mutants. Valine is also used for protein synthesis, and therefore when low concentrations of valine are used a fraction of it is consumed and, if the fraction is big enough, inhibition is relieved. For this reason we never use a concentration of valine lower than 20 ,gg/ml, but we add 50 ,ug of leucine per ml to decrease the intracellular concentration of valine. Valr mutants which need leucine to express the resistance to valine are more often transport mutants, but they can also be regulatory mutants. In this case, leucine acts at the transport level by decreasing valine uptake and can usually be substituted by threonine. 
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